enGene Therapeutics Inc. (ENGN) Cash and securities
- Total cash · latest quarter (USD): Value $266.32M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-07-31..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-07-31..
Cash and securities
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $266.32M | Cash and cash equivalents plus current marketable securities. Period ending 2026-07-31. $41.02M + $225.29M ≈ $266.32M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 41.02M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 225.29M USD | Marketable Securities, Current |
| Cash and current securities | 266.32M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-07-31 | $266.32M | (m) | $41.02M | $225.29M | (m) |
| 2026-04-30 | $258.46M | (m) | $29.83M | $228.64M | (m) |
| 2026-01-31 | $275.95M | (m) | $36.61M | $239.34M | (m) |
| 2025-10-31 | $193.74M | (m) | $50.15M | $143.58M | (m) |
| 2025-07-31 | $201.91M | (m) | $32.62M | $169.29M | (m) |
| 2025-04-30 | $217.39M | (m) | $57.55M | $159.85M | (m) |
| 2025-01-31 | $213.81M | (m) | $62.35M | $151.47M | (m) |
| 2024-10-31 | $238.33M | (m) | $173.00M | $65.33M | (m) |
| 2024-07-31 | (m) | (m) | $257.68M | (m) | (m) |
| 2024-04-30 | (m) | (m) | $264.81M | (m) | (m) |
| 2024-01-31 | (m) | (m) | $85.65M | (m) | (m) |
| 2023-10-31 | (m) | (m) | $81.52M | (m) | (m) |
| 2022-10-31 | (m) | (m) | $20.43M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |